

Literatura

- Anderson JLC, et al. Autoantibodies to apolipoprotein A-1 as independent predictors of cardiovascular mortality in renal transplant recipients. *J Clin Med*. 2019;8:E948.
- Aronis KN, et al. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. *Metabolism*. 2013;62:1279-1286.
- Aronson JK. Meyler's side effects of endocrine and metabolic drugs. Elsevier. 2009;367-381.
- Ashoor IF, et al. Prevalence of cardiovascular disease risk factors in childhood glomerular diseases. *J Am Heart Assoc*. 2019;8:e012143.
- Astrup A, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. *Lancet*. 2009;374:1606-1616.
- Badheka AO, et al. Influence of obesity on outcomes in atrial fibrillation. *Am J Med*. 2010;123:646-651.
- Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. *Drugs*. 2011;71:1441-1467.
- Baggio LL. Biology of incretins: GLP-1 and GIP. *Gastroenterology*. 2007;132:2131-2157.
- Beckman JA, et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA*. 2002;287:2570-2581.
- Ben SI, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? *Mol Cancer Ther*. 2010;9:1092-1099.
- Bethel MA, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *Lancet Diabetes Endocrinol*. 2018;6:105-113.
- Bi Y, et al. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis. *Diabetes Metab Res Rev*. 2019:e3142.
- Bodmer M, et al. Long-term metformin use is associated with decreased risk of breast cancer. *Diabetes Care*. 2010;33:1304-1308.
- Brackett CC. Clarifying metformin's role and risks in liver dysfunction. *J Am Pharm Assoc*. 2010;50:407-410.
- Burhanullah MH, et al. Neuropsychiatric symptoms as risk factors for cognitive decline in clinically normal older adults: The cache county study. *Am J Geriatr Psychiatry*. 2019:S1064-7481 [epub ahead of print].
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. *Cell Metabolism*. 2013;17:819-837.

- Carmona-Iragui M, et al. Down syndrome, Alzheimer disease and cerebral amyloid angiopathy: the complex triangle of brain amyloidosis. *Dev Neurobiol.* 2019 [epub ahead of print].
- Cinti S. Transdifferentiation properties of adipocytes in the adipose organ. *Am J Physiol Endocrinol Metab.* 2009;297:977-986.
- Cinti S. UCP1 protein: The molecular hub of adipose organ plasticity. *Biochimie.* 2017;134:71-76.
- Collier A et al. Cancer has overtaken cardiovascular disease as the commonest cause of death in Scottish type 2 diabetes: a population based study (The Ayrshire diabetes follow-up cohort study). *J Diabetes Investig.* 2019. doi: 10.1111/jdi.13067 [epub ahead of print].
- Cosentino F, Grant P, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J.* 2019;00:1-69.
- Coutinho J, et al. The relationship between glucose and incident cardiovascular event. *Diabetes Care.* 1999;22:233-240.
- Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia.* 2009;52:1766-1777.
- Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2018;41:2669-2701.
- De Fronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes.* 2009;58:773-795.
- Di Dalmazi G, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. *Lancet Diabetes Endocrinol.* 2014;2:396-405.
- Di Tomo P, et al. Liraglutide mitigates TNF- α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women. *Diabetes Metab Res Rev.* 2017;33.
- Diamant M, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *Lancet.* 2010;375:2234-2243.
- Doria A, et al. Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. *JAMA.* 2008;300:2389-2397.
- Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet.* 2005;366:1279-1289.

- Dorner TE, Rieder A. Obesity paradox or reverse epidemiology: is high body weight a protective factor for various chronic conditions. *Dtsch Med Wochenschr.* 2010;135:413–418.
- Drinkwater JJ, et al. A systematic review of risk factors for cataract in type 2 diabetes. *Diabetes Metab Res Rev.* 2019;35:e3073.
- Eilat-Tsanani S, Mor E, Schonmann Y. Statin use over 65 years of age and all-cause mortality: A 10-year follow-up of 19 518 people. *J Am Geriatr Soc.* 2019; doi: 10.1111/jgs.16060 [epub ahead of print].
- Eisen A, et al. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. *Eur Heart J.* 2016;37:3576–3584.
- Elmaraezy A, et al. Risk of cataract among interventional cardiologists and catheterization lab staff: A systematic review and meta-analysis. *Catheter Cardiovasc Interv.* 2017;90:1–9.
- Elyan BMP, et al. Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases. *BMC Nephrol.* 2019;20:237.
- Evans MRB, et al. Revolution in acute ischaemic stroke care: a practical guide to mechanical thrombectomy. *Pract Neurol.* 2017;17:252–265.
- Ferrannini E, et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. *Diabetes Care.* 2013;36:4015–4021.
- Ferrannini E, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care.* 2010;33:2217–2224.
- Ferrannini E, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. *J Clin Invest.* 2014;124:499–508.
- Fischer M, NcMurray J. *Diabetic cardiology.* Hoboken: Wiley, 2010.
- Fisman EZ, Tenenbaum A (eds.). *Cardiovascular diabetology. Advances in Cardiology.* Vol. 45. Basel: Karger, 2008.
- Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA.* 2013;309:71–82.
- Fonseca V. *Clinical diabetes.* New York: Saunders, 2006.
- Forette, et al. Systolic hypertension in Europe investigators. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. *Arch Intern Med.* 2002;162:2046–2052.
- Foretz M, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. *J Clin Invest.* 2010;120:2355–2369.

- Fried M, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m²: an integrative review of early studies. *Obes Surg.* 2010;20:776–790.
- Fried M, Svačina Š, Owen K. Bariatriká chirurgie a diabetes. In: Svačina Š, et al. *Trendy soudobé diabetologie*. Praha: Galén, 2005.
- Frühbeck G, et al. PRDM16: the interconvertible adipo-myocyte switch. *Trends Cell Biol.* 2009;19:141–146.
- Fu Y, et al. Antidepressants use and risk of cataract development: a systematic review and meta-analysis. *BMC Ophthalmol.* 2018;18:31.
- Garber AJ, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm 2016: Executive summary. *Endocr Pract.* 2016;22:84–113.
- Gaviola ML, et al. Statin effects on incidence, treatment success, and mortality of *Clostridium difficile* infections. *J Pharm Pract.* 2019;897190019854956 [epub ahead of print].
- Gelfand JM, et al. Risk of myocardial infarction in patients with psoriasis. *JAMA.* 2006;296:1735–1741.
- Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet.* 2019;394:121–130.
- Giordano A, et al. White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. *Eur J Endocrinol.* 2014;170:159–171.
- Golay A. Metformin and body weight. *Int J Obes.* 2008;32:61–72.
- Gotrik MR, et al. Advancements in aptamer discovery technologies. *Acc Chem Res.* 2016;49:1903–1910.
- Gough SC, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. *Lancet Diabetes Endocrinol.* 2014;2:885–893.
- Graham LC, et al. Exercise prevents obesity-induced cognitive decline and white matter damage in mice. *Neurobiol Aging.* 2019;80:154–172.
- Gras V, et al. Effect of metformin on survival rate in experimental sepsis. *Diabetes Metab.* 2006;32:147–150.
- Guzon-Illescas O, et al. Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. *J Orthop Surg Res.* 2019;14:203.
- Haluzík M, Svačina Š. Gliptiny. In: Haluzík M, et al. *Trendy v diabetologii*, 12. ed. Praha: Galén, 2008.
- Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá fronta, 2011.

- Haluzík M, Svačina Š. Metabolický syndrom a jaderné receptory PPAR. Praha: Grada, 2004.
- Han S, et al. CTRP1 protects against diet-induced hyperglycemia by enhancing glycolysis and fatty acid oxidation. *J Nutr Biochem*. 2016;27:43–52.
- Hartwell MJ, et al. Risk factors for 30-day readmission following knee arthroscopy. *J Knee Surg*. 2019 [epub ahead of print].
- Heerspink HJ, et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. *Diabetes Obes Metab*. 2016;18:590–597.
- Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. 2018;392:1519–1529.
- Hester RE, Harrison RM: Endocrine disrupting chemicals. *Issues in Environmental Science* 12. London Royal Society of Chemistry, 1999.
- Hoffman LB, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. *Neurology*. 2009.
- Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2017;377:1228–1239.
- Holman RR, Watkins PJ (eds). UKPDS: the first 30 years. Oxford: Wiley-Blackwell, 2008.
- Hong CT, et al. Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson's disease. *Parkinsonism Relat Disord*. 2019;S1353-8020(19)30285-8.
- Hong JW, et al. The prevalence and factors associated with hearing impairment in the Korean adults: the 2010–2012 Korea National Health and Nutrition Examination Survey (observational study). *Medicine (Baltimore)*. 2015;94:e611.
- Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2019;381:841–851.
- Chaiyasothi T, et al. Effects of non-statin lipid-modifying agents on cardiovascular morbidity and mortality among statin-treated patients: A systematic review and network meta-analysis. *Front Pharmacol*. 2019;10:547.
- Chakravarthy U, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. *BMC Ophthalmol*. 2010;10:31.
- Chang HL, et al. A predictive model for progression of CKD. *Medicine (Baltimore)*. 2019;98:e16186.

- Chang M, et al. Hearing loss as a risk factor for cognitive impairment and loss of synapses in the hippocampus. *Behav Brain Res*. 2019;372:112069 [epub ahead of print].
- Cho NJ, et al. Association of intracranial artery calcification with cognitive impairment in hemodialysis patients. *Med Sci Monit*. 2019;25:5036-5043.
- Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015;38:140-149.
- Inzucchi SE: Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. *Diabetes Care*. 2018;41:e4-e5.
- Jansen HJ, et al. Start of insulin therapy in patients with type 2 diabetes mellitus promotes the influx of macrophages into subcutaneous adipose tissue. *Diabetologia*. 2013;56:2573-2581.
- Javanmard P, Duan D, Geer EB. Mortality in patients with endogenous Cushing's syndrome. *Endocrinol Metab Clin North Am*. 2018;47:313-333.
- Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. *N Engl J Med*. 2006;355:779-787.
- Jenkins M, Goldsmith D. Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence? *Curr Opin Cardiol*. 2012;27:429-440.
- Ji S, et al. Effects of statins therapy on mean platelet volume in patients with risk of cardiovascular diseases: A systematic review and meta-analysis. *Biosci Rep*. 2019 [epub ahead of print].
- Jialal I, Singh G. Management of diabetic dyslipidemia: An update. *World J Diabetes*. 2019;10:280-290.
- Journy NMY, et al. Hyperthyroidism, hypothyroidism, and cause-specific mortality in a large cohort of women. *Thyroid*. 2017;27:1001-1010.
- Kanazawa I. Usefulness of metformin in diabetes-related bone disease. *Clin Calcium*. 2009;19:1319-1325.
- Kanukula R, et al. Does co-administration of antihypertensive drugs and statins alter their efficacy and safety? A systematic review and meta-analysis of randomized controlled trials. *J Cardiovasc Pharmacol*. 2019;73:352-358.
- Karen I, a kol. Prediabetes. Doporučený postup pro praktické lékaře. SVL, 2018.
- Karen I, Svačina Š (eds). Diabetes mellitus v primární péči. 3. rozšířené vydání. Praha: Axonite, 2017.
- Khan SU, et al. Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type

- 9 inhibitors: A systematic review and meta-analysis. *J Clin Lipidol*. 2019;pii: S1933-2874(19)30212-0.
- Klarin D, et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. *Nat Med*. 2019 [epub ahead of print].
- Kohut T, Robbins J, Panganiban J. Update on childhood/adolescent obesity and its sequela. *Curr Opin Pediatr*. 2019 [epub ahead of print].
- Korbonits M (ed.). *Obesity and metabolism*. Basel: Karger, 2008.
- Kosiborod M, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL 2 study. *J Am Coll Cardiol*. 2018;71:2628-2639.
- Kristensen SL, et al. Cardiovascular mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol*. 2019.
- Lainscak M, et al. The obesity paradox in chronic disease: facts and numbers. *J Cachexia Sarcopenia Muscle*. 2012;3:1-4.
- Landman GW, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. *Diabetes Care*. 2010;33:322-326.
- Lavie CJ, et al. Obesity and the „obesity paradox“ in cardiovascular diseases. *Clin Pharmacol Ther*. 2011;90:23-25.
- Law PJ, et al. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. *Nat Commun*. 2019;10:2154.
- Lee S, et al. Obesity, metabolic abnormality, and knee osteoarthritis: A cross-sectional study in Korean women. *Mod Rheumatol*. 2014:1-6.
- Lethin C, et al. Prevalence of dementia diagnoses not other specified in eight European countries: a cross-sectional cohort study. *BMC Geriatr*. 2019;19:172.
- Libby G, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. *Diabetes Care*. 2009;32:1620-1625.
- Loftfield E, et al. Prospective investigation of serum metabolites, coffee drinking, liver cancer incidence, and liver disease mortality. *J Natl Cancer Inst*. 2019 [epub ahead of print].
- Luchsinger JA, Noble JM, Scarmeas N. Diet and Alzheimer's disease. *Curr Neurol Neurosci Rep*. 2007;7:366-372.
- Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. *Am J Geriatr Psychiatry*. 2007;15:762-771.
- Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. *Am J Epidemiol*. 2001;154:635-641.

- Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. *Eur J Pharmacol.* 2008;585:119-129.
- MacDonald MR, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. *Eur Heart J.* 2008;29:1377-1385.
- Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2016;375:311-322.
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2016 [e-publikace].
- Matsumoto K, et al. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. *Diabetes Res Clin Pract.* 2004;64:225-228.
- McAuley PA, et al. The obesity paradox and cardiorespiratory fitness. *J Obes.* 2012;2012:951-958.
- Molad J, et al. Vascular and neurodegenerative markers for the prediction of post-stroke cognitive impairment: Results from the TABASCO study. *J Alzheimers Dis.* 2019 [epub ahead of print].
- Monami M, et al. Metabolic syndrome and cardiovascular mortality in older type 2 diabetic patients: a longitudinal study. *J Gerontol A Biol Sci Med Sci.* 2008;63:646.
- Morelli V, Arosio M, Chiodini I. Cardiovascular mortality in patients with subclinical Cushing. *Ann Endocrinol.* 2018;79:149-152.
- Muendlein A, et al. The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events. *Atherosclerosis.* 2019;286:1-6.
- Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. *N Engl J Med.* 2019;380:171-176.
- Nam SW, et al. Risk factors of presenile nuclear cataract in health screening study. *BMC Ophthalmol.* 2018;18:263.
- Nathan DM, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care.* 2007;30:753-759.
- Nauck M. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. *Diabetologia.* 1986;29:46-52.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med.* 2017; doi: 10.1056/NEJMoa1611925.
- Onuma H, et al: The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells. *Biochem Biophys Res Commun.* 2014;451:339-344.

- ORIGIN Trial Investigators: Gerstein HC, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367:319–328.
- Owan TE, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med*. 2006;355:251–259.
- Pajvani UB, Accili D. The new biology of diabetes. *Diabetologia*. 2015;58:2459–2468.
- Palmer SC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. *JAMA*. 2016;316:313–324.
- Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care: A first analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) study. *Circulation*. 2019 [epub ahead of print].
- Pedersen BK. Muscle as a secretory organ. *Compr Physiol* 2013;3(3):1337–62.
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019; doi: 10.1056/NEJMoa1811744 [epub ahead of print].
- Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med*. 2015;373:2247–2257.
- Phillips CM. Nutrigenetics and metabolic disease: current status and implications for personalised nutrition. *Nutrients*. 2013;5:32–57.
- Pickworth CK, et al. Randomized controlled trials investigating the relationship between dietary pattern and high-sensitivity C-reactive protein: a systematic review. *Nutr Rev*. 2019;77:363–375.
- Pivonello R, et al. Complications of Cushing's syndrome: state of the art. *Lancet Diabetes Endocrinol*. 2016;4:611–629.
- Pongrac Barlovic D, Tikkanen-Dolenc H, Groop PH. Physical activity in the prevention of development and progression of kidney disease in type 1 diabetes. *Curr Diab Rep*. 2019;19:41
- Prokofyeva E, et al. Cataract prevalence and prevention in Europe: a literature review. *Acta Ophthalmol*. 2013;91:395–405.
- Prudente S, et al. Genetic variant at the GLUL locus predicts all-cause mortality in patients with type 2 diabetes. *Diabetes*. 2015;64:2658–2663.
- Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. *Ann Rev Med*. 1993;44:121–131.
- Rendell MS. Albiglutide: a unique GLP-1 receptor agonist. *Expert Opin Biol Ther*. 2016 [e-publikace].
- Rosenstock J, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in

- type 2 diabetes with mild hyperglycaemia. *Diabetes Obes Metab.* 2013;15:1154–1160.
- Salsali A, et al. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. *Diabetes Obes Metab.* 2016;18:1034–1040.
- Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet.* 2010;375:735–742.
- Scirica BM, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. *Circulation.* 2014;130:1579–1588.
- Scoditti E, et al. Role of diet in chronic obstructive pulmonary disease prevention and treatment. *Nutrients.* 2019;11:E1357.
- Scragg RKR. Overview of results from the vitamin D assessment (ViDA) study. *J Endocrinol Invest.* 2019 [epub ahead of print].
- Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. *Eur Heart J.* 2015;36:1718–1727.
- Shaw KA, Edelman AB. Obesity and oral contraceptives. *Best Pract Res Clin Endocr Metab.* 2013;27:55–65.
- Silveira CRA, et al. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. *BMC Neurol.* 2019;19:1252–1253.
- Silverberg DS, et al. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? *J Nephrol.* 2004;17:749–761.
- Simopoulos AP, Ordovas, JM (ed.). *Nutrigenetics and nutrigenomics.* Basel: Karger, 2004.
- Sinclair AJ, et al. European diabetes working party for older people 2011. Clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes working party for older people. *Diabetes Metab.* 2011;37:27–38.
- Sjostrom, C. D. et al.: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. *Obes Res.* 1999; 5: 477–84.
- Slapničková M. S červy proti obezitě. *Vesmír.* 2012;91:666–672.
- Smedby KE, et al. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. *Cancer Epidemiol Biomarkers Prev.* 2006;15:2069–2077.
- Smith L, et al. The new face of hyperlipidemia management: proprotein convertase subtilisin/kexin inhibitors (PCSK-9) and their emergent role

- as an alternative to statin therapy. *J Pharm Pharm Sci.* 2016;19:137–146.
- Smyth B, Perkovic V. New hypoglycemic agents and the kidney: what do the major trials tell us. *F1000Res.* 2018;7:1844.
- Starup-Linde J, et al. Skeletal fragility in type 2 diabetes mellitus. *Endocrinol Metab (Seoul).* 2018;33:339–351.
- Stránská Z, Svačina Š. Myokiny – hormony svalové tkáně. *Vnitr Lek.* 2015;61:365–368.
- Suri S, et al. Association of midlife cardiovascular risk profiles with cerebral perfusion at older ages. *JAMA Netw Open.* 2019;2:e195776
- Svačina Š (ed.). *Poruchy metabolismu a výživy.* Praha: Galén, 2010.
- Svačina Š a kol. *Klinická dietologie.* Praha: Grada, 2008.
- Svačina Š, Tesař V. Proč volit po metforminu gliflozin? Hypertenze a kardiovaskulární prevence *Časopis české společnosti pro hypertenzi.* 2019;1:40–42.
- Svačina Š. *Antidiabetika, historie, současnost a perspektivy.* Praha: Axonite, 2017.
- Svačina Š. Barevné tukové buňky a diabetes. *Česká diabetologie,* 2019;2:4–6.
- Svačina Š. Diabetická osteopatie: onemocnění kdysi sporné a pravděpodobně významné. *Vnitr Lek.* 2010;56:1225–1227.
- Svačina Š. *Léčba obézního diabetika.* Praha: Mladá Fronta, 2018.
- Svačina Š. Metabolický syndrom a onemocnění kůže. *Čas Lék Česk.* 2008;147:307–310.
- Svačina Š. Metformin – antidiabetikum první volby. *Vnitr Lek.* 2010;56:1225–1227.
- Svačina Š. Mikrobiální flóra trávicího traktu a diabetes. *Vnitr Lek.* 2015;4:361–364.
- Svačina Š. Nádory ledvin močového měchýře a prostaty u obezity a diabetu. *Vnitr Lek.* 2008;54:464–467.
- Svačina Š. Nádory ledvin, močového měchýře a prostaty u obezity a diabetu. *Vnitr Lek.* 2008;54:464–467.
- Svačina Š. Nový pohled na antidiabetika vzhledem ke klinickému účinku a k tzv. de Fronzovu oktetu. *Med Promoci.* 2016;172:1–4.
- Svačina Š. Nutrigenetika a nutrigenomika. *Čas Lék Čes.* 2007;11.
- Svačina Š. *Obezitologie a teorie metabolického syndromu.* Praha: Triton, 2013.
- Svačina Š. Proč a jak působí inzulinové přípravky na hmotnost. *Vnitr Lek.* 2014;60:448–453.
- Svačina Š. Proč a jak snižují glifloziny krevní tlak. In Widimský J. *Symposium Arteriální hypertenze – současné trendy.* Praha: Triton, 2018.

- Syllaba J. Diabetes a ateroskleróza. In Riedl O a kol. Aterosklerosa – nejnovější poznatky. Praha: Státní zdravotnické nakladatelství, 1957, s. 74–85.
- Šmahelová A, Lášticová M. Diabetologie pro farmaceuty. Praha: Mladá fronta, 2011.
- Šmahelová A. Akutní komplikace diabetu. Praha: Triton, 2006.
- Štulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? *Diabetes Res Clin Pract.* 2010;88:125–131.
- Tan C, et al. Statin, cholesterol, and sICH after acute ischemic stroke: systematic review and meta-analysis. *Neurol Sci.* 2019; doi: 10.1007/s10072-019-03995-0 [epub ahead of print].
- Tan HE, et al. Associations between cardiovascular disease and its risk factors with hearing loss. A cross-sectional analysis. *Clin Otolaryngol.* 2018;43:172–181.
- Tang T, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. *Cochrane Database Syst Rev.* 2010;1:CD003053.
- Thompson AM, Trujillo JM. Advances in the treatment of type 2 diabetes: impact of dulaglutide. *Diabetes Metab Syndr Obes.* 2016;9:125–36.
- Tomlinson B, et al. Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. *Expert Opin Drug Metab Toxicol.* 2016:1–5.
- Tomlinson B, et al. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. *Expert Opin Investig Drugs.* 2016;25:1167–1179.
- Tziomalos K, et al. Nonalcoholic fatty liver disease and statins. *Metabolism.* 2015;64:1215–1223.
- Udeh-Momoh CT, et al. Cortisol, amyloid- β , and reserve predicts Alzheimer's disease progression for cognitively normal older adults. *J Alzheimers Dis.* 2019 [epub ahead of print].
- Uehara H, et al. Adipose tissue: Critical contributor to the development of prostate cancer. *J Med Invest.* 2018;65:9–17.
- UKPDS Group: Effect of intensive blood-glucose control with metformin on complications in overweight with type 2 diabetes (UKPDS 34). *Lancet.* 1998;352:85.
- Ussar S, Vienberg SG, Kahn CR. Receptor antibodies as novel therapeutics for diabetes. *Sci Transl Med.* 2011;3:113p.
- van der Lee SJ, et al. A nonsynonymous mutation in PLGG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. *Acta Neuropathol.* 2019 [epub ahead of print].

- Vermaete NV, et al. Physical activity and risk of lymphoma: a meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2013;22:1173-1184.
- Waller HT. Height, weight and mortality. The Norwegian experience. *Acta Med Scand.* 1984;679:1-56.
- Wahidi N, Lerner AJ. Blood pressure control and protection of the aging brain. *Neurotherapeutics.* 2019 [epub ahead of print].
- Wang C, et al. Risk factors for acute kidney injury in patients with acute myocardial infarction. *Chin Med J (Engl).* 2019 Jun 28. [Epub ahead of print]
- Wang YX, et al. Friend or foe: Multiple roles of adipose tissue in cancer formation and progression. *J Cell Physiol.* 2019.
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med.* 2016;375:323-334.
- WHO guidelines approved by the Guidelines review committee. Risk reduction of cognitive decline and dementia: WHO guidelines. Geneva: World Health Organization, 2019.
- Wiernsperger NF. Review: 50 years later: is metformin vascular drug with antidiabetic properties? *Brit J Diabetes Vasc Dis.* 2007;7:204-210.
- Wilson JH. Statin use protective for chronic rhinosinusitis in a nationally representative sample of the United States. *Laryngoscope.* 2019; doi: 10.1002/lary.28085 [epub ahead of print].
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2019;380:347-357, doi: 10.1056/NEJMoa1812389.
- Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. *Cancer Causes Control.* 2009;20:1617-1622.
- Wroge J, Williams NT. Glucagon-like peptide-1 (GLP-1) receptor agonists in cardiac disorders. *Ann Pharmacother.* 2016 [e-publikace].
- Xu W, Qiu C, Gatz M, et al. Mid- and late-life diabetes in relation to the risk of dementia: A population-based twin study. *Diabetes.* 2009;58:71-77.
- Zaccardi F, et al. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. *Ann Intern Med.* 2016;164:102-113.
- Zelniker TA et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. *Circulation.* 2019;139:2022-2031.
- Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type

- 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet*. 2019;393:31–39.
- Zhao CN, et al. Fruits for prevention and treatment of cardiovascular diseases. *Nutrients*. 2017;9:E598.
- Zhao D, et al. Diabetes, glucose metabolism, and glaucoma: the 2005–2008 national health and nutrition examination survey. *PLoS One*. 2014;9:e112460.
- Zinman B, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). *Diabetologia*. 2018;61:48–57.
- Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373:2117–2128.